<DOC>
	<DOCNO>NCT00686894</DOCNO>
	<brief_summary>Subjects give 3 infusion infliximab accord label week 0 , 2 , 6 . Subjects follow maximum 18 week relapse . This study ass ability Power Doppler Ultrasonography ( PDUS ) reliable marker enthesitis response relapse subject treat infliximab .</brief_summary>
	<brief_title>Enthesitis With Ultra Sonography Doppler Spondyloarthropathies Treated With Infliximab ( Study P04440 )</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylarthropathies</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Demonstrate willingness participate study , adhere dose visit schedule , comply procedure sign write informed consent . Negative serum pregnancy test Week 0 . Men woman 18 year either sex race . Free clinically relevant disease SpA would principal investigator 's and/or sponsor 's opinion , interfere conduct study evaluation . Eligible antitumor necrosis factor ( TNF ) treatment accord applicable local guideline . Fulfill follow criterion : European Spondyloarthropathy Study group ( ESSG ) Classification Criteria , and/or Amor Criteria , and/or New York modify criterion . Disease duration SpA &gt; 6 month . Incomplete response nonsteriodal antiinflammatory drug ( NSAID ) . Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) &gt; 4 include item 2 ( axial pain ) &gt; =3 scale 0 10 . At least 1 enthesitis assess PDUS . Creactive protein ( CRP ) twice upper normal laboratory value inflammatory signal magnetic resonance imaging ( MRI ) spine sacroiliac joint within last 3 month . Practicing adequate contraception study 6 month last infusion . Week 0 laboratory test must meet protocol criterion . Is female pregnant , intend become pregnant study ( within 6 month receive last infusion ) ; Is female nursing , intend nursing study within 6 month receive last infusion ; Has childbearing potential without contraception throughout study 6 month receive last infusion . Has observe designate washout period prohibit medication outline protocol ; Has clinically significant deviation appropriate reference range physical examination , Chest Xray , , investigator 's judgment , may interfere study evaluation affect subject safety ; Is situation condition , opinion investigator , may interfere optimal participation study . Is staff , affiliate , family member staff personnel directly involve study ; Is allergic sensitivity study drug excipients ; Has intolerance contraindication infliximab . Has history allergy murine product . Is uncooperative signed consent form . Can understand protocol . Has participate study within 3 month prior inclusion . Had treatment unstable dos analgesic drug ( paracetamol , phenylbutazone , morphine ) steroid , NSAID , immunosuppressive agent , include methotrexate , within 4 week prior inclusion . Had Intra articular steroid within 4 week prior inclusion . Had Previous treatment infliximab Had previous treatment etanercept , adalimumab TNF agent within 2 last month . Had history , ongoing recurrent medical condition follow : Infectious disease , include limited chronic renal infection , chronic chest infection ( e.g . bronchectasis ) , sinusitis , recurrent urinary tract infection ( recurrent pyelonephritis chronic nonremeting cystitis ) open , drain infected skin wound , ulcer . Serious infection ( ) ( hepatitis , pneumonia pyelonephritis ) within 3 month prior inclusion . Malignancy within previous 5 year exception basal cell carcinoma skin treat evidence recurrence . Active tuberculosis previous history non treat insufficiently treat tuberculosis . Patients positive intradermal tuberculosis test accord local recommendation For patient could contact person tuberculosis , inclusion possible specific condition depend local recommendation issue France , Denmark , Hungary , Italy , Spain . Herpes zoster ( shingle ) infection within 2 month prior first infusion Opportunistic infection , e.g . cytomegalovirus , Pneumocystis carinii pneumonia , aspergillosis , histoplasmosis atypical mycobacterium infection . Has follow clinical condition : Severe , progressive uncontrolled renal , hepatic , hematologic , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , psychiatic cerebral disease Known infect human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C Known lymphoproliferative disease , include lymphoma , sign suggestive lymphoproliferative disease , lymphadenoma unusual size localization splenomegaly . Have receive live ( attenuate ) vaccination last 30 day Have treat monoclonal antibody fusion protein except etanercept , adalimumab anti TNF agent Leukopenia &lt; 3,500/mm^3 , Hemoglobin &lt; 9g/dl , thrombopenia &lt; 100,000/mm^3 . Congestive heart failure ( CHF ) include medically control , asymptomatic CHF unstable hemodynamic cardiac condition . Scheduled surgical intervention time study . Multiple sclerosis symptomatic demyelination central nervous system . Subjects history drug abuse alcoholism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>